Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anaptysbio (ANAB) EBT Margin (2016 - 2025)

Anaptysbio's EBT Margin history spans 10 years, with the latest figure at 83.68% for Q4 2025.

  • For Q4 2025, EBT Margin rose 17084.0% year-over-year to 83.68%; the TTM value through Sep 2025 reached 67.62%, up 32524.0%, while the annual FY2024 figure was 159.1%, 79433.0% up from the prior year.
  • EBT Margin reached 83.68% in Q4 2025 per ANAB's latest filing, up from 30.23% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 83.68% in Q4 2025 to a low of 3237.84% in Q1 2022.
  • Average EBT Margin over 5 years is 923.92%, with a median of 433.95% recorded in 2022.
  • Peak YoY movement for EBT Margin: crashed -313115bps in 2021, then skyrocketed 263239bps in 2022.
  • A 5-year view of EBT Margin shows it stood at 3075.07% in 2021, then skyrocketed by 86bps to 442.68% in 2022, then fell by -6bps to 468.32% in 2023, then skyrocketed by 81bps to 87.16% in 2024, then soared by 196bps to 83.68% in 2025.
  • Per Business Quant, the three most recent readings for ANAB's EBT Margin are 83.68% (Q4 2025), 30.23% (Q3 2025), and 173.34% (Q2 2025).